Capstone Investment Advisors’s Exact Sciences EXAS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-251,384
Closed -$25.5M 1671
2025
Q4
$25.5M Buy
251,384
+242,647
+2,777% +$19.5M 0.05% 153
2025
Q3
$478K Sell
8,737
-988
-10% -$49.4K ﹤0.01% 1401
2025
Q2
$517K Buy
+9,725
New +$494K ﹤0.01% 1127
2025
Q1
Sell
-18,315
Closed -$1.03M 1515
2024
Q4
$1.03M Sell
18,315
-20,983
-53% -$1.31M ﹤0.01% 1058
2024
Q3
$2.68M Buy
+39,298
New +$2.22M 0.01% 639
2024
Q2
Sell
-6,408
Closed -$443K 2198
2024
Q1
$443K Buy
+6,408
New +$405K ﹤0.01% 1632
2022
Q3
Sell
-13,164
Closed -$519K 1687
2022
Q2
$519K Buy
+13,164
New +$704K ﹤0.01% 1225
2019
Q4
Sell
-46,402
Closed -$4.19M 1405
2019
Q3
$4.19M Buy
+46,402
New +$5.29M 0.03% 507
2017
Q3
Sell
-9,500
Closed -$336K 602
2017
Q2
$336K Buy
+9,500
New +$293K 0.01% 473

Other funds holding EXAS

Capstone Investment Advisors's EXAS Position: Q1 2026 in Review

Capstone Investment Advisors sold out of Exact Sciences (EXAS) in Q1 2026, closing a stake of 251,384 shares — an estimated $25.5M sold.

Capstone Investment Advisors first reported a position in EXAS in Q2 2017 and held it in 9 quarters. The position peaked at $25.5M in Q4 2025. 7 funds tracked by Wall St. Rank hold EXAS as of Q1 2026.

  • Capstone Investment Advisors reported no remaining Exact Sciences position as of Q1 2026 after selling out during the quarter.
  • Capstone Investment Advisors sold 251,384 Exact Sciences shares in Q1 2026, an estimated $25.5M.
  • Capstone Investment Advisors first reported a position in Exact Sciences in Q2 2017 and held it in 9 quarters.
  • Capstone Investment Advisors's Exact Sciences position peaked at $25.5M in Q4 2025.
  • 7 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2026.

Based on Capstone Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.